1-Ethyl-2,3-difluoro-4-propan-2-ylbenzene

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-Ethyl-2,3-difluoro-4-propan-2-ylbenzene
• 英文别名: 1-ethyl-2,3-difluoro-4-propan-2-ylbenzene
• 化学式: C₁₁H₁₄F₂
• 分子量: 184.23
• InChiKey: CYUKNJHADKIGQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Compounds useful as kinase inhibitors
  申请人：Loxo Oncology, Inc.

  公开号：US10464905B2

  公开（公告）日：2019-11-05

  This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

  本发明涉及新型化合物。本发明的化合物是酪氨酸激酶抑制剂。具体来说，本发明的化合物可用作布鲁顿酪氨酸激酶（BTK）的抑制剂。本发明还考虑将这些化合物用于治疗可通过抑制布鲁顿酪氨酸激酶治疗的疾病，例如癌症、淋巴瘤、白血病和免疫性疾病。
• Modulators of P97 AAA ATPase activity
  申请人：UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US11214560B2

  公开（公告）日：2022-01-04

  The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.

  本技术涉及抑制或调节 p97 的方法以及在此类方法中有用的化合物和组合物。可使用本技术的化合物和组合物治疗的疾病和病症包括但不限于抗菌感染、抗病毒感染、癌症和易受 p97 抑制或调节治疗的神经退行性疾病。
• DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS
  申请人：Lomox Limited

  公开号：EP3523313B1

  公开（公告）日：2021-05-05
• COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Loxo Oncology, Inc.

  公开号：US20190000806A1

  公开（公告）日：2019-01-03

  This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
• P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS
  申请人：Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

  公开号：US20200155536A1

  公开（公告）日：2020-05-21

  The present disclosure relates generally to methods for treating multisystem degenerative diseases, hematological malignancies, solid tumors, and neurodegenerative disorders.